# OnCo record her2-ihc-3-plus (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/her2-ihc-3-plus/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "her2-ihc-3-plus" ;
  schema:name "HER2 IHC 3+ (HER2-positive by immunohistochemistry)"@en ;
  schema:alternateName "HER2 IHC 3+"@en, "HER2 3+"@en, "IHC 3+"@en, "HER2 overexpression"@en, "HER2-positive IHC"@en, "HER2 protein overexpression"@en ;
  schema:description "IHC 3+ means strong, complete membrane staining for HER2 in more than 10 percent of tumour cells. It is HER2-positive without needing a gene test and is the gate for trastuzumab, its combinations and antibody-drug conjugates in breast, stomach, biliary and, since 2024, any solid tumour."@en ;
  schema:url <https://onco.cc/biomarkers/her2-ihc-3-plus/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2>, <https://doi.org/10.1200/JCO.2018.77.8738> ;
  onco:tag "biomarker", "her2" ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-2-plus/>, <https://onco.cc/biomarkers/her2-ihc-1-plus/>, <https://onco.cc/biomarkers/her2-ihc-0/>, <https://onco.cc/biomarkers/her2-low-ihc/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/>, <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/margetuximab/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/her2-testing-assays/> ;
  onco:terms <https://onco.cc/terms/her2-positive/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/dual-her2-blockade/> .